Literature DB >> 3137688

Characterization of platelet binding of heparins and other glycosaminoglycans.

M Sobel1, B Adelman.   

Abstract

The binding of glycosaminoglycans to intact washed human platelets was studied. The platelet binding of a 3H-labeled unfractionated heparin was saturable and reached equilibrium in 10-15 minutes. Heparin binding was specific: a 50-fold molar excess of an equivalent unlabeled heparin displaced up to 90% of labeled heparin, while chondroitin sulfate A and hyaluronic acid minimally displaced the binding of labeled heparin. Low molecular weight heparin fragments showed intermediate efficacy in displacing the binding of unfractionated [3H]heparin. Dextran sulfate (Mr 8,000, sulfation 17%) was as potent as unfractionated heparin in displacing binding, while neutral dextrans were ineffective. We observed that platelet activation by the calcium ionophore A23187 increased heparin binding by 2 to 3-fold, principally by enhancement of binding capacity not binding affinity. This process of heparin binding to the platelet surface may mediate some of the reported effects of heparin on platelet behavior.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3137688     DOI: 10.1016/0049-3848(88)90341-6

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  12 in total

Review 1.  Antithrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents.

Authors:  M I Furman; A L Frelinger III; A D Michelson
Journal:  Curr Cardiol Rep       Date:  2000-09       Impact factor: 2.931

2.  Heparin promotes platelet responsiveness by potentiating αIIbβ3-mediated outside-in signaling.

Authors:  Cunji Gao; Brian Boylan; Juan Fang; David A Wilcox; Debra K Newman; Peter J Newman
Journal:  Blood       Date:  2011-03-02       Impact factor: 22.113

3.  Heparin modulates the conformation and signaling of platelet integrin αIIbβ3.

Authors:  Mayumi Yagi; Jacqueline Murray; Kurt Strand; Scott Blystone; Gianluca Interlandi; Yasuo Suda; Michael Sobel
Journal:  Thromb Res       Date:  2011-12-23       Impact factor: 3.944

Review 4.  Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis.

Authors:  Sheridan M Hoy; Lesley J Scott; Greg L Plosker
Journal:  Drugs       Date:  2010-07-09       Impact factor: 9.546

5.  Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo.

Authors:  M Sobel; P M McNeill; P L Carlson; J C Kermode; B Adelman; R Conroy; D Marques
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

6.  Platelets are dominant contributors to hypercoagulability after injury.

Authors:  Jeffrey N Harr; Ernest E Moore; Theresa L Chin; Arsen Ghasabyan; Eduardo Gonzalez; Max V Wohlauer; Anirban Banerjee; Christopher C Silliman; Angela Sauaia
Journal:  J Trauma Acute Care Surg       Date:  2013-03       Impact factor: 3.313

7.  Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma.

Authors:  Charles A Karcutskie; Arjuna Dharmaraja; Jaimin Patel; Sarah A Eidelson; Anish B Padiadpu; Arch G Martin; Gabriel Lama; Edward B Lineen; Nicholas Namias; Carl I Schulman; Kenneth G Proctor
Journal:  JAMA Surg       Date:  2018-02-01       Impact factor: 14.766

Review 8.  Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease.

Authors:  Susan M Cheer; Christopher J Dunn; Rachel Foster
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Heparin binding domain peptides of antithrombin III: analysis by isothermal titration calorimetry and circular dichroism spectroscopy.

Authors:  R Tyler-Cross; M Sobel; D Marques; R B Harris
Journal:  Protein Sci       Date:  1994-04       Impact factor: 6.725

Review 10.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.